Replies to post #149698 on Biotech Values

[mcbio]

ARQL - The CEO noted that they had reached the number of events for an interim look about two months ago. Do you happen to know if that's ahead of schedule? They should probably be announcing the interim results soon.

I saw people mention on Twitter about how that is ahead of schedule and how that's potentially a bearish sign but that seems silly to me as it could just as easily be a larger number of patients in the control group, as opposed to tivantinib arm, that account for the bulk of the events.